Loading
Colon Cancer / Breast Cancer / Prostate Cancer · Observational Study
ClinicalTrials.gov · August 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an ongoing observational registry study registered at ClinicalTrials.gov collecting blood samples from cancer patients to measure immune suppressor cells before and after treatment and correlate findings with clinical outcomes. No results have been posted in this registry record, and the study remains in recruitment phase.
Observational. Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer; age from 18 Years; accepts healthy volunteers. Intervention: Healthy Volunteers; Participants. n = 1,750. 1 site: United States.
This is an ongoing observational registry study registered at ClinicalTrials.gov collecting blood samples from cancer patients to measure immune suppressor cells before and after treatment and correlate findings with clinical outcomes. No results have been posted in this registry record, and the study remains in recruitment phase.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is an ongoing observational registry study with no results posted; it describes planned blood collection and correlative analysis in cancer patients without reporting any outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT00034216). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 1750 participants (ESTIMATED). Conditions: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer. Primary outcome measures: Undertake genetic analysis of both prokaryotic and eukaryotic samples for advanced mutational analysis. , ongoing; Correlate analysis results with clinical parameters such as demographics, toxicities, and treatment outcomes. , ongoing; Collection of tissue, urine, saliva, stool and blood components, which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and circulating tumor cells (cTC), of human subjects. , ongoing. Brief summary: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment. ...
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.